Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18809943 | 1.00 | BTK (0.52) | BTKCHEK1RPS6KB1PDPK1AURKA | |
| SCHEMBL23223089 | 0.98 | BTK (0.51) | BTKCHEK1RPS6KB1PDPK1AURKA | |
| SCHEMBL23409130 | 0.94 | BTK (0.52) | BTKCHEK1RPS6KB1KCNH2EGFR | |
| SCHEMBL22909562 | 0.90 | BTK (0.53) | BTKKCNH2 | |
| SCHEMBL19533478 | 0.90 | BTK (0.64) | BTKCHEK1RPS6KB1PDPK1AURKA | |
| SCHEMBL25060365 | 0.90 | BTK (0.64) | BTKCHEK1RPS6KB1PDPK1AURKA | |
| SCHEMBL19256762 | 0.89 | CHEK1 (0.45) | BTKCHEK1RPS6KB1PDPK1AURKA | |
| SCHEMBL22737476 | 0.88 | BTK (0.56) | BTK | |
| SCHEMBL24041268 | 0.88 | BTK (0.58) | BTKKCNH2EGFR | |
| SCHEMBL20881645 | 0.85 | BTK (0.50) | BTKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020239103-A1 | BTK INHIBITOR RING DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2020-12-03 | — | — | WO | disclosed |
| EP-2882751-B1 | DEUTERATED IBRUTINIB | CONCERT PHARMACEUTICALS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20180044339-A1 | PROCESS FOR PREPARING IBRUTINIB | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2018-02-15 | — | — | US | disclosed |
| EP-3257855-A1 | METHOD FOR PREPARING IBRUTINIB | Shanghai Dude Medical Science and Technology Co., Ltd. (CN) | 2017-12-20 | — | — | EP | disclosed |
| WO-2017137446-A1 | PROCESS FOR THE SYNTHESIS OF STABLE AMORPHOUS IBRUTINIB | AZAD PHARMACEUTICAL INGREDIENTS AG (CH) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044339-A1 | PROCESS FOR PREPARING IBRUTINIB | BTK, SYK, ABL1 | BTK 1/4885CHEK1 21/4885RPS6KB1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.